Impact of COVID-19 Pandemic on the Paediatric Oncology Service at the National Cancer Institute, Sudan: A Retrospective Descriptive Study
Authors:
Preprint
- 30 May 2026
- preprint
- Published by Springer Nature in Research Square
Abstract
Background The COVID-19 pandemic disrupted cancer care globally, with disproportionate effects in low- and middle-income countries. Sudan faced compounded challenges from pre-existing healthcare fragility, political instability, and classification as a Level 4 COVID-19 transmission risk zone. Objectives We aimed to describe the pandemic’s impact on pediatric oncology service utilization, treatment delivery, healthcare access, and clinical outcomes at Sudan’s National Cancer Institute. Methods We conducted a retrospective descriptive study of 100 pediatric cancer patients (aged 0–15 years) attending the National Cancer Institute, University of Gezira, between March and September 2020. Data were collected using structured questionnaires and analyzed with multivariable logistic regression. Results Patient volume declined 89% compared to the 2019 baseline. Treatment modifications occurred in 28% of patients, missed appointments in 26%, and in-hospital mortality reached 35%—nearly double pre-pandemic rates and 4–6 times higher than in other low- and middle-income country settings. Low socioeconomic status independently predicted missed appointments (OR 3.2, 95% CI 1.4–7.3) and treatment modification (OR 2.8, 95% CI 1.2–6.6). Conclusions Indirect pandemic effects—service disruption and access barriers—proved more lethal than direct SARS-CoV-2 infection, exacerbating pre-existing health inequities.Keywords
All Related Versions
- Version 1, 2026-05-30, Research Square
- Published version: BMC Health Services Research.
This publication has 10 references indexed in Scilit:
- Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort studyThe Lancet Oncology, 2021
- Global effect of the COVID-19 pandemic on paediatric cancer care: a cross-sectional studyThe Lancet Child & Adolescent Health, 2021
- Changes in the Number of US Patients With Newly Identified Cancer Before and During the Coronavirus Disease 2019 (COVID-19) PandemicJAMA Network Open, 2020
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort studyThe Lancet, 2020
- The COVID‐19 pandemic: A rapid global response for children with cancer from SIOP, COG, SIOP‐E, SIOP‐PODC, IPSO, PROS, CCI, and St Jude GlobalPediatric Blood & Cancer, 2020
- Estimating the total incidence of global childhood cancer: a simulation-based analysisThe Lancet Oncology, 2019
- Childhood cancer burden: a review of global estimatesThe Lancet Oncology, 2019
- Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countriesThe Lancet, 2018
- International incidence of childhood cancer, 2001–10: a population-based registry studyThe Lancet Oncology, 2017
- Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trialThe Lancet Oncology, 2014